GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds

Recently reported HIV-1 capsid (CA) inhibitors GS-CA1 and GS-6207 (an analog of GS-CA1) are first-in-class compounds with long-acting potential. Reportedly, both compounds have greater potency than currently approved anti-HIV drugs. Due to the limited access to experimental data and the compounds th...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Kamal, Gallazzi, Fabio, Hill, Kyle J., Burke, Donald H., Lange, Margaret J., Quinn, Thomas P., Neogi, Ujjwal, Sönnerborg, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613529/
https://www.ncbi.nlm.nih.gov/pubmed/31312185
http://dx.doi.org/10.3389/fmicb.2019.01227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613529/
https://www.ncbi.nlm.nih.gov/pubmed/31312185
http://dx.doi.org/10.3389/fmicb.2019.01227

Ejemplares similares